Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Hepatocellular 7Carcinoma, Non-Small-Cell Lung 6Solid Tumor 3Neoplasms 3Advanced Solid Tumors 3Stomach Neoplasms 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Advanced Solid Tumor 2Advanced Lung Cancer 2Uterine Cervical Neoplasms 1Squamous NSCLC 1SCLC 1Ovarian Neoplasms 1Osteosarcoma 1Non-Squamous Non-Small Cell Lung Cancer 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Melanoma 1MSI-H 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Gastrointestinal Diseases 1Esophageal Diseases 1Carcinoma, Squamous Cell 1Advanced/Metastatic Solid Malignancies 1Advanced or Metastatic Solid Tumors 1Advanced Solid Tumours 1

Interventions

sintilimab 2Injections 2aflutinib 1Chlorogenic Acid 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Lung Cancer × sintilimab × Clear all
NCT04672356 2023-06-22

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
19 enrolled
Thoracic

Advanced Lung Cancer

NCT04672369 2023-06-22

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
42 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡